Lilly Announces Date for Investor Web Call; Plans To Share Phase III Dulaglutide Data (NYSE:LLY)
INDIANAPOLIS, May 27, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a conference call on June 16 for the media and investment community to provide detailed updates for dulaglutide, its investigational glucagon-like receptor agonist (GLP-1) being studied for the treatment of type 2 diabetes. The call, which is being held in conjunction with the 74th American Diabetes Association Scientific Sessions, will include updates on Phase III data for dulaglutide, including details on clinical trials vs. liraglutide and insulin glargine.
Lilly Announces Date for Investor Web Call; Plans To Share Phase III Dulaglutide Data (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.